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ABSTRACT
In this report, we systematically examined the role of telomerase activity in
lung and ovarian cancer stem cell (CSC) propagation. For this purpose, we indirectly
gauged telomerase activity, by linking the hTERT-promoter to eGFP. Using lung
(A549) and ovarian (SKOV3) cancer cells, transduced with the hTERT-GFP reporter,
we then employed GFP-expression levels to fractionate these cell lines into GFPhigh and GFP-low populations. We functionally compared the phenotype of these
GFP-high and GFP-low populations. More specifically, we now show that the cancer
cells with higher telomerase activity (GFP-high) are more energetically activated,
with increased mitochondrial mass and function, as well as increased glycolytic
activity. This was further validated and confirmed by unbiased proteomics analysis.
Cells with high telomerase activity also showed an increased capacity for stem cell
activity (as measured using the 3D-spheroid assay) and cell migration (as measured
using a Boyden chamber approach). These enhanced biological phenotypes were
effectively inhibited by classical modulators of energy metabolism, which target
either i) mitochondrial metabolism (i.e., oligomycin) or ii) glycolysis (i.e., 2-deoxyglucose), or iii) by using the FDA-approved antibiotic doxycycline, which inhibits
mitochondrial biogenesis. Finally, the level of telomerase activity also determined the
ability of hTERT-high cells to proliferate, as assessed by measuring DNA synthesis
via EdU incorporation. Consistent with these observations, treatment with an FDAapproved CDK4/6 inhibitor (PD-0332991/palbociclib) specifically blocked the
propagation of both lung and ovarian CSCs. Virtually identical results were obtained
with breast CSCs, which were also highly sensitive to palbociclib at concentrations
in the nanomolar range. In summary, CSCs with high telomerase activity are among
the most energetically activated, migratory and proliferative cell sub-populations.
These observations may provide a mechanistic explanation for tumor metabolic
heterogeneity, based on telomerase activity. FDA-approved drugs, such as doxycycline
and palbociclib, were both effective at curtailing CSC propagation. Thus, these FDAapproved drugs could be used to target telomerase-high proliferative CSCs, in multiple
cancer types. Finally, our experiments also allowed us to distinguish two different
cellular populations of hTERT-high cells, one that was proliferative (i.e., replicative
immortality) and the other that was non-proliferative (i.e., quiescent). We speculate
that the non-proliferative population of hTERT-high cells that we identified could be
mechanistically involved in tumor dormancy.
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INTRODUCTION

flow cytometry. The phenotypic behavior of GFP(+) and
GFP(-) populations was then compared quantitatively. In
this analysis, the GFP(+) cell population represents the
hTERT-high cell population, while the GFP(-) cells serve
as a critical internal control for phenotypic comparison.

Telomerase is a critical enzyme that serves an
important functional role in a plethora of biological
processes, ranging from organismal development and
regeneration to chronological aging [1] and the onset of
the malignant phenotype in human cancers [2–4]. Yet,
despite years of study, many of the functions of telomerase
still remain unknown or poorly defined. Mechanistically,
telomerase consists of both RNA-based and proteinaceous
components or subunits: telomerase RNA (TERC) and
telomerase reverse transcriptase (TERT) [5]. High levels of
telomerase expression are observed in normal stem cells [6]
and cancer cells [7]. In both these normal and pathological
contexts, telomerase expression functionally confers
immortalization [8], allowing cells to bypass senescence and
to multiply past fifty to seventy divisions [9].
Several research groups have now exploited human
telomerase (hTERT) to allow for the enrichment of cancer
stem-like cells (CSCs). More specifically, Yu et al., 2013
[10], placed a 1.5-kB fragment of the hTERT promoter
upstream of eGFP. Recombinant transduction of this hTERTeGFP reporter into osteosarcoma cell lines then allowed the
purification of a telomerase enriched cell population by flow
cytometry. They also directly showed that hTERT-high cells
derived from an osteosarcoma cell line were more stem-like
and underwent anchorage-independent growth. Furthermore,
the hTERT-high osteosarcoma cell population was more
invasive, with a greater capacity for drug-resistance and
metastatic dissemination. Thus, this innovative approach
to CSC enrichment has already shown great promise
[11], but needs to be further validated and extended to the
characterization of various epithelial cancer types, such as
non-small cell lung cancer and ovarian carcinomas, among
others.
In this report, we applied this general approach to
two independent cell lines, namely A549 and SKOV3
cells, which were originally derived from human
cancer patients suffering from lung and ovarian cancer,
respectively. Then, we focused on the functional and
molecular characterization of the hTERT-high cell
population isolated by flow cytometry. More specifically,
we employed unbiased proteomics analysis [12, 13] and
validation via functional metabolic studies, which allowed
us to identify new therapeutic strategies for the eradication
of the hTERT-high cell population.

hTERT-high CSCs show elevated levels of ALDH
activity and higher mitochondrial mass
Figure 1A shows that hTERT-high cells form
3D-spheroids (>50-μm) with a greater efficiency, up to
2-fold higher, as observed by comparing the GFP(+) and
GFP(-) cell populations. Virtually identical results were
obtained with both A549 and SKOV3 cell lines, indicating
that this is a conserved property of hTERT-high CSCs.
Similarly, hTERT-high cells were significantly enriched
in ALDH-activity, a well-established marker of CSCs
(Figure 1B, 1C).
Because hTERT is mechanistically linked to
increased mitochondrial biogenesis [11], we next
examined the status of mitochondrial mass in hTERThigh cells. For this purpose, we directly correlated the
eGFP fluorescence signal (representing hTERT activity)
with the intensity of MitoTracker Deep Red (a marker of
mitochondrial mass). Importantly, Figure 2 demonstrates
that GFP(+) hTERT-high cells have a higher mitochondrial
mass, as predicted [11]. Virtually identical results were
also obtained with another mitochondrial probe, namely
MitoTracker Orange, which provides a measure of
mitochondrial membrane potential (Figure 3).
As a further test of the specificity of this
experimental system, we next employed a well-established
telomerase inhibitor (MST-312; 1 μM) [10]. Figure 4A
shows that treatment with MST-312 significantly reduces
the ability of hTERT-high cells to form 3D-spheroids (a
measure of anchorage-independent growth capacity).
Consistent with this finding MST-312 treatment also
reduces the expression of eGFP and mitochondrial mass
in the hTERT-high cell population, as seen by fluorescence
microscopy (Figure 4B). Thus, eGFP intensity does indeed
reflect telomerase activity, and is functionally connected to
mitochondrial mass [11].

hTERT-high CSCs are more metabolically
active and their propagation and migration are
inhibited by targeting mitochondrial function
To better dissect the role of hTERT activity in tumor
cell metabolism, we next employed the Seahorse XFe96
bioenergetic analyzer, to directly measure metabolic
flux. For this purpose, we systematically compared
the metabolic properties of the GFP(+) and GFP(-) cell
populations. Figures 5 and 6 illustrate that the GFP(+)
population is clearly more metabolically active than the
GFP(-) cells, with significant increases in both oxygen
consumption and glycolytic rates. This is consistent with

RESULTS
Here, we used an established approach based on
telomerase activity, to begin to dissect the role of hTERT
in tumor cell heterogeneity. Briefly, A549 (lung) and
SKOV3 (ovarian) cancer cell lines were stably-transduced
with a sensitive eGFP reporter system for the fluorescent
detection of high telomerase transcriptional activity. This
allowed us to isolate the hTERT-high cell population by
www.impactjournals.com/oncotarget
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the increase in mitochondrial mass that we observed
experimentally using the MitoTracker probes. Moreover,
unbiased proteomics analysis of the GFP(+) and the GFP() cell populations revealed that hTERT-high cells show the
up-regulation of key mitochondrial proteins and glycolytic
enzymes. These results are summarized in Tables 1 and
2. Importantly, note that the expression of the MT-CO2
protein was significantly increased (by ~4 to 6-fold) in
GFP(+) cell populations. Since MT-CO2 is specifically
encoded by mitochondrial DNA, this finding is indicative
of an increased capacity for driving new mitochondrial
biogenesis. Interestingly, a comparison of Tables 1 and
2 indicates that the following eight metabolism-related
proteins were commonly upregulated in hTERT-high
cells, derived from both the A549 and SKOV3 cell
populations (AK2, ATP5B, HSPA9, HSPD1, LDHB,
MT-CO2, PRKDC, and PYGB) (See Supplementary Table
1). These metabolism-related gene products are likely to
be specific targets of hTERT in CSCs, and are mainly
related to mitochondrial biogenesis.

To functionally validate the role of oxidative
mitochondrial metabolism and glycolysis in the
propagation of hTERT-high cells, we used a battery of
well-established metabolic inhibitors, to target these
essential metabolic pathways. To inhibit mitochondrial
function, we employed i) oligomycin (an ATP-synthase
inhibitor), ii) XCT790 (an ERRA/PGC1A inhibitor)
and iii) doxycycline (an inhibitor of mitochondrial
protein synthesis). Similarly, for inhibiting glycolysis,
we utilized 2-deoxy-glucose (2-DG). Briefly, 2-DG
is a chemically-modified form of glucose in which
the 2-hydroxyl group is replaced by hydrogen; as a
consequence, it cannot undergo further glycolysis.
Figure 7 shows that both inhibitors of glycolysis and
mitochondrial metabolism were similarly effective in
halting the propagation of hTERT-high cells. This may
be related to the fact that glycolysis inhibitors will also
ultimately reduce oxidative mitochondrial metabolism,
as the final product of glycolysis (pyruvate) is further
metabolized by mitochondria.

Figure 1: Validation of the cellular models: hTERT-high cells show an increased capacity for 3D-sphere formation and
are enriched in ALDH activity. A. 3D-sphere formation. A549 and SKOV3 cells stably-transduced with the hTERT-eGFP reporter

were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations. GFP(+) cells were operationally defined as those with
the top 10% eGFP intensity, while GFP(-) cells were defined as those with the lowest 10% eGFP intensity, unless stated otherwise. The
GFP-high and GFP-low cell populations were then plated in low-attachment plates for 3D-spheroid assays and analyzed after 5 days of
culture. Note that GFP(+) A549 and GFP(+) SKOV3 cells both form 3D-spheroids with a near 2-fold increased efficiency, as compared to
their corresponding GFP(-) counterparts. B and C. ALDH activity profile. A549 and SKOV3 cells stably-transduced with the hTERT-eGFP
reporter were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations. GFP(+) cells were operationally defined as those
with the top 5% eGFP intensity, while GFP(-) cells were defined as those with the lowest 5% eGFP. Then, they were counter-stained with
AldeRed to identify the ALDH(+) cell population. Representative tracings are shown in panel B, in the presence or absence of the ALDH
inhibitor (DEAB). Panel C shows that the GFP(+) cell populations were enriched in ALDH activity relative to the GFP(-) cell population.
Therefore, higher telomerase activity correlates with increased 3D-spheroid formation and increased ALDH activity. ALDH intensity is
expressed as mean fluorescence intensity of 3 experiments. N=3 independent experiments, with 2 technical replicates per experiment. Bar
graphs are shown as the mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.005, ***p < 0.0001.
www.impactjournals.com/oncotarget
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Figure 2: hTERT-high cells show a significant increase in mitochondrial mass. A549 and SKOV3 cells stably-transduced with

the hTERT-eGFP reporter were subjected to flow cytometry to identify the GFP(+) and GFP(-) cell populations. In addition, the cells were
also counter-stained with MitoTracker Deep Red to correlate their mitochondrial mass with GFP intensity. Five different cell populations
with different GFP intensities were considered in this analysis. Note that panel A shows that mitochondrial mass increases with increasing
GFP levels in hTERT-GFP A549 cells. Panel B illustrates that similar results were observed with hTERT-GFP SKOV3 cells. Therefore,
higher telomerase activity correlates with increased mitochondrial mass in both cell lines. N=3 independent experiments, with 2 technical
replicates for each experiment. Bar graphs are shown as the mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.001.

Figure 3: hTERT-high cells show a significant increase in mitochondrial membrane potential/activity. Cell populations

were analyzed as outlined in Figure 2, except that MitoTracker Orange was used as a marker of mitochondrial membrane potential. Note
that in A549 cells, mitochondrial membrane potential increases with increasing GFP levels. Therefore, higher telomerase activity correlates
with increased mitochondrial membrane potential in A549 cells. N=3 independent experiments, 2 technical replicates per experiment. Bar
graphs are shown as the mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.001.
www.impactjournals.com/oncotarget
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hTERT-high cells also appear to be more migratory,
as observed by quantitatively comparing the migration
of the GFP(+) and GFP(-) cell populations (Figure 8A).
To test if this phenotype is strictly dependent on intact
mitochondrial function, we examined the effects of
two mitochondrial inhibitors, namely oligomycin and
XCT790. Note that treatment with these mitochondrial
inhibitors is sufficient to significantly reduce migration in
the hTERT-high CSCs (Figure 8B, 8C).

the GFP(+) and GFP(-) cell populations, by employing EdUincorporation and FACS analysis. Remarkably, our results
indicate that the GFP(+) cell population is the predominant
proliferating cell population, whereas the GFP(-) population
does not undergo significant proliferation (Figure 9).
Importantly, these results directly show that the hTERT-high
cells are the most significant proliferating cell population
and, therefore, they should be targeted therapeutically.
To this end, we next evaluated the effects of a wellestablished CDK4/6 inhibitor, namely palbociclib, on CSC
propagation in A549, SKOV3 and MCF7 cells. For this
purpose, we used 3D-spheroid formation as a measure
of CSC-activity. Figure 10 (panels A-C) illustrates
that palbociclib significantly inhibits the propagation
of CSCs, in lung, ovarian and breast cancer cell lines,
with an IC-50 near 100 nM. Thus, palbociclib and other

hTERT-high CSCs are highly proliferative and
can be effectively targeted with the CDK4/6
inhibitor palbociclib
To better understand the role of hTERT in cell
propagation, we assessed DNA synthesis (S-phase) in both

Figure 4: Inhibition of telomerase activity effectively reduces 3D-spheroid formation, GFP intensity and mitochondrial
mass. A. 3D-sphere formation A549 and SKOV3 cells stably-transduced with the hTERT-eGFP reporter were subjected to FACS sorting to

isolate the GFP(+) cell population. Then, the phenotype of the GFP(+) population was analyzed in the absence or presence of the telomerase
inhibitor. Note that treatment with the telomerase-inhibitor MST-312 (1 μM) decreased 3D-sphere formation in GFP(+) A549 cells (1.75
fold, left panel) and in GFP(+) SKOV3 cells (2 fold, right panel). Bar graphs are shown as the mean ± SEM; t-test, two-tailed test **p <
0.005, ***p < 0.0001. B. Immuno-fluorescence analysis. Treatment of adherent cells with the telomerase-inhibitor MST-312 (1 μM and 5
μM) decreases GFP and MitoTracker Deep Red staining, in a dose-dependent fashion. Representative immunofluorescence images show
that 1 μM MST-312 causes a slight decrease of the GFP and MitoTracker signal in both cell lines. A more dramatic effect is observed after
treatment with 5 μM MST-312 in both hTERT-GFP A549 cells and hTERT-GFP SKOV3 cells. Original magnification, 40x. Scale bar 20
μm. Therefore, 3D-sphere formation, GFP expression and mitochondrial mass are strictly dependent on telomerase activity, as predicted.
www.impactjournals.com/oncotarget
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CDK4/6 inhibitors may be useful to clinically target the
proliferative CSC population.

a model system. To this end, we employed a sensitive
reporter system to monitor telomerase functionally,
by placing the hTERT endogenous promoter sequence
upstream of eGFP. Then, we isolated hTERT-high cells
by FACS, by collecting the GFP(+) cell population. The
GFP(-) cell population served as a critical internal control
for these studies. Most remarkably, hTERT-high cells
showed significant increases in both glycolytic metabolism

DISCUSSION
Here, we explored the contribution of hTERTactivity to the generation and maintenance of the CSC
population, using ovarian and lung cancer cell lines as

Figure 5: Mitochondrial respiration and glycolysis are both significantly enhanced in hTERT-high A549 cells. A549

cells stably-transduced with the hTERT-eGFP reporter were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations.
Then, the metabolic profiles of these 2 cell populations was then analyzed quantitatively. Briefly, hTERT-GFP A549 sup-populations were
isolated by sorting based on GFP levels, and grown as monolayers for 20 hours, prior to metabolic analysis using the Seahorse XFe96
analyzer. A. Oxygen consumption. A representative tracing of an OCR experiment is shown in the top panel. The bar graphs in the lower
panel show that maximal respiration is increased in GFP(+) cells as compared to GFP(-) cells by 1.32 fold. Also, the spare respiratory
capacity is significantly higher in GFP(+) cells by 1.5 fold. Data are presented in the bar graphs as a combination of N=3 independent
experiments. Bar graphs are shown as the mean ± SEM, t-test, two-tailed test. B. Glycolysis rate. A representative tracing of an ECAR
experiment is shown in the top panel. The bar graph in the lower panel shows that the glycolysis (measured after addition of glucose) is
increased in GFP(+) cells as compared to GFP(-) cells by 1.78 fold, and the glycolytic capacity (measured after oligomycin addition) is
increased by 1.74 fold. Data are presented in the bar graphs as a combination of N=3 independent experiments. Bar graphs are shown as the
mean ± SEM; t-test, two-tailed test *p < 0.05, **p < 0.005, ***p < 0.0001.
www.impactjournals.com/oncotarget
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and mitochondrial-driven oxygen consumption. This was
indeed confirmed and validated further by employing
proteomics analysis. hTERT-high cells also showed an
enhanced ability to undergo anchorage-independent
cell growth (3D-spheroid formation), as well as cell
migration [13]. Both of these cellular phenotypes have
been previously shown to be associated with increased
“stem cell activity” in CSC populations. Importantly,
these “stemness” phenotypes were effectively inhibited
by treatment with compounds that halt mitochondrial
metabolism (i.e., oligomycin, XCT790, doxycycline)

[13–15] or ii) glycolysis (i.e., 2-deoxy-glucose) [16, 17].
Surprisingly, hTERT-high cells were highly proliferative,
as evidenced by a dramatic increase in their capacity
to undergo DNA-synthesis, when measured via EdU
incorporation. Similarly, palbociclib (an FDA-approved
CDK4/6 inhibitor) [18, 19] dramatically blocked the
propagation of CSCs, as measured using 3D-spheroid
formation as a functional assay, with an IC-50 in the
range of 100 nM. Overall, our findings provide a new
mechanistic appreciation for how telomerase activity
contributes as a driver of tumor metabolic heterogeneity

Figure 6: Mitochondrial respiration and glycolysis are both significantly enhanced in hTERT-high SKOV3 cells. SKOV3

cells stably-transduced with the hTERT-eGFP reporter were subjected to FACS sorting to isolate the GFP(+) and GFP(-) cell populations.
Then, the metabolic profiles of these 2 cell populations was then analyzed quantitatively. Briefly, hTERT-GFP SKOV3 sup-populations
were isolated by sorting based on GFP levels, and grown as monolayers for 20 hours, prior to metabolic analysis using the Seahorse XFe96
analyzer. A. Oxygen consumption. A representative tracing of an OCR experiment is shown in the top panel. The bar graphs in the lower
panel shows that basal respiration, proton leak and ATP production are all increased in GFP(+) cells as compared to GFP(-) cells. Data are
presented in the bar graphs as a combination of N=3 independent experiments. Bar graphs are shown as the mean ± SEM; t-test, two-tailed
test. B. Glycolysis rate. A representative tracing of an ECAR experiment is shown in the top panel. The bar graphs in the lower panel show
glycolysis (measured after addition of glucose) is increased in GFP(+) cells as compared to GFP(-) cells by 1.5 fold, and the glycolytic
capacity (measured after oligomycin addition) is also increased by 1.2 fold. Data are presented in the bar graphs as a combination of N=5
independent experiments. Bar graphs are shown as the mean ± SEM, t-test, two-tailed test. *p < 0.05, ***p < 0.0001.
www.impactjournals.com/oncotarget
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Table 1: Proteomics: Key Molecules Up-regulated in hTERT-GFP(+) A549 Lung Cancer Cells Isolated by FACS
Symbol

Fold-Upregulation
(GPF(+)/GFP(-))

Description

Mitochondrial-related proteins
ALDH2

Aldehyde dehydrogenase, mitochondrial

Infinity

AK2

Adenylate kinase 2, mitochondrial

27.20

ATP5B

ATP synthase subunit beta

9.48

IMMT

Mitochondrial inner membrane protein

9.20

MRPL49

Mitochondrial ribosomal protein L49

7.12

PRKDC

DNA-dependent protein kinase catalytic subunit

6.26

HSPA9

Heat shock 70 kDa protein 9

6.00

MT-CO2

Cytochrome c oxidase subunit 2, mt-DNA encoded

3.99

NDUFS2

NADH-ubiquinone oxidoreductase 49 kDa subunit, mitochondrial

3.76

ETFA

Electron transfer flavoprotein subunit alpha, mitochondrial

2.83

SLC25A10

Mitochondrial dicarboxylate carrier

2.39

ATP5O

ATP synthase subunit O, mitochondrial

2.36

VDAC1

Voltage-dependent anion-selective channel protein 1

2.27

SLC25A5

Mitochondrial Carrier; Adenine Nucleotide Translocator, Member 5

1.99

HSPD1

60 kDa heat shock protein, mitochondrial

1.98

LDHB

L-lactate dehydrogenase B

50.93

G6PD

Glucose-6-phosphate 1-dehydrogenase

17.85

TPI1

Triosephosphate isomerase 1

17.41

PGK1

Phosphoglycerate kinase 1

9.49

ALDOA

Fructose-bisphosphate aldolase

3.32

PGD

6-phosphogluconate dehydrogenase, decarboxylating

3.21

PKM2

Pyruvate kinase

1.93

Glycogen phosphorylase, brain form

2.23

Glycolysis and PPP

Glycogen-related
PYGB

Proteomic analysis of hTERT-GFP A549 cells. Data are derived from the analysis of FACS sorted cell populations. The
fold-increase of certain key molecules in GFP(+) cells is shown, relative to GFP(-) cells. Note that several protein targets
related to mitochondria, glycolysis, and glycogenolysis are increased in GFP(+) cells.

(Figure 11). Most notably, hTERT-high cells were the most
energetic, migratory and proliferative cell population.
Thus, FDA-approved drugs (such as doxycycline and
palbociclib) should be considered as new therapeutic
strategies for targeting hTERT-high cells, in various cancer
types (Figure 11).
Similarly, several reports have now directly
shown a connection between hTERT function and
mitochondrial activity. This occurs through a telomerase
www.impactjournals.com/oncotarget

and p53-based signaling pathway, which converges on
PGC1A/B, a major mitochondrial transcription factor
[20–22]. Specifically, aging-related studies directly
demonstrate that impairment of hTERT function leads to
mitochondrial decline, via p53 over-expression [23, 24],
which ultimately inactivates PGC1A/B function [25].
Just the opposite occurs during cancer development,
where p53 is often inactivated resulting in activation
of PGC1A and mitochondrial function [26]. Thus,
9875
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Table 2: Proteomics: Key Molecules Up-regulated in hTERT-GFP(+) SKOV3 Ovarian Cancer Cells Isolated by FACS
Symbol

Fold-Upregulation
(GPF(+)/GFP(-))

Description

Mitochondrial-related proteins
MRPL15

Mitochondrial ribosomal protein L15

11.65

SLC25A10

Mitochondrial dicarboxylate carrier

10.11

DUT

Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial

9.48

VDAC2

Voltage-dependent anion channel 2

7.23

COX5A

Cytochrome c oxidase subunit 5A, mitochondrial

7.08

MT-CO2

Cytochrome c oxidase subunit 2, mt-DNA encoded

6.08

PRKDC

DNA-dependent protein kinase catalytic subunit

5.90

SHMT2

Serine hydroxymethyltransferase, mitochondrial

5.71

HSPD1

60 kDa heat shock protein, mitochondrial

5.44

FECH

Ferrochelatase, mitochondrial

5.23

ATP5B

ATP synthase subunit beta

4.54

SOD2

Superoxide dismutase 2

4.27

YARS2

Tyrosine--tRNA ligase, mitochondrial

4.18

DLST

Dihydrolipoyllysine-residue succinyltransferase component of
2-oxoglutarate dehydrogenase complex, mitochondrial

4.10

TUFM

Elongation factor Tu, mitochondrial

4.00

ALDH1B1

Aldehyde dehydrogenase X, mitochondrial

3.27

PMPCA

Mitochondrial-processing peptidase subunit alpha

3.25

CS

Citrate synthase

3.25

MTCH2

Mitochondrial carrier homolog 2

3.10

ECI1

Enoyl-CoA delta isomerase 1, mitochondrial

2.41

AK2

Adenylate kinase 2, mitochondrial

2.41

SDHA

Succinate dehydrogenase flavoprotein subunit, mitochondrial

2.39

HSPA9

Stress-70 protein, mitochondrial

2.38

ACO2

Aconitase 2, mitochondrial

1.82

IDH3A

Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial

1.52

LDHAL6B

L-lactate dehydrogenase A-like 6B

8.51

PGK2

Phosphoglycerate kinase 2

6.91

ENO3

Enolase

4.16

PKLR

Pyruvate kinase isozymes R/L

3.71

ENO2

Enolase

3.56

HK1

Hexokinase-1

3.25

LDHB

L-lactate dehydrogenase B

3.08

Glycogen phosphorylase, brain form

1.63

Glycolysis and PPP

Glycogen-related
PYGB

Proteomic analysis of hTERT-GFP SKOV3 cells. Data are derived from the analysis of FACS sorted cell populations.
The fold-increase of certain key molecules in GFP(+) cells is shown, relative to GFP(-) cells. Note that several protein
targets related to mitochondrial metabolism and glycolysis are increased in GFP(+) cells.
www.impactjournals.com/oncotarget
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our current studies are consistent with a functional
link between hTERT-high cells and mitochondrial
metabolism, driving increased metabolic activation of
this highly proliferative cell population.
Perhaps most unexpected is our observation
that the CSC population is highly proliferative and
can be targeted with a CDK4/6 inhibitor. However,
this should not be too surprising, because telomerase
activity is functionally linked to cell immortalization
and proliferation [27], as well as escape from cell cycle

arrest and senescence. Moreover, these experiments did
allow us to distinguish two different cellular populations
of hTERT-high cells, i) one that was proliferative and
ii) the other that was non-proliferative (Figure 12).
We speculate that the non-proliferative population of
hTERT-high cells may be involved in tumor dormancy
[28] and could be re-activated with the appropriate
stimulus, driving tumor recurrence and metastasis [29].
Most importantly, our current work provides a novel
strategy to potentially isolate the non-proliferative

Figure 7: 3D-spheroid formation relies both on mitochondrial function and glycolytic metabolism. A-C. Mitochondrial

inhibitors. Mitochondrial function is required for the efficient clonal expansion and anchorage-independent growth of CSCs. Indeed,
oligomycin A, an inhibitor of the mitochondrial ATP synthase, inhibits 3D-sphere formation in the GFP(+) cell population isolated from
A549 and SKOV3 cells (panel A). Complementary results were also obtained with two other well-established mitochondrial inhibitors,
namely XCT790 (panel B) and doxycycline (panel C). XCT790 is a well-established ERRα inverse agonist that effectively blocks the
function of PGC1A, the major mitochondrial transcription factor. Doxycycline functions as an inhibitor of mitochondrial biogenesis, by
inhibiting mitochondrial protein synthesis at the level of the mito-ribosome. D. Inhibition of glycolysis. Glycolytic metabolism is important
for 3D-spheroids. Note that treatment with the glycolytic inhibitor 2-deoxy-glucose (2-DG) significantly reduces sphere formation. Bar
graphs show the mean ± SEM, t-test, two-tailed test. *p < 0.05, **p < 0.005, ***p < 0.001.
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population of hTERT-high cells, allowing further
mechanistic studies on tumor dormancy in vitro.
Palbociclib (PD-0332991; from Pfizer) was first
approved by the FDA on February 3, 2015 as the firstline treatment for advanced post-menopausal ER+,
HER2-negative breast cancer, in combination with
letrozole [30]. It is an orally bioavailable and potent
second generation CDK4/6 inhibitor. Mechanistically,
it induces a G1-phase arrest in cell cycle progression.
Remarkably, palbociclib nearly doubled progressionfree survival (PFS) in this patient population (from
10.2 months to 20.2 months) [30]. Thus, palbociclib
received designation as a ‘Breakthrough Therapy’ and
gained accelerated approval from the FDA. There are
currently at least 12 other palbociclib trials in breast
cancer patients that are now ongoing, most of which are
targeting advanced and metastatic disease states [30].
And, other CDK inhibitors are also being clinically
developed to target metastatic disease: Ribociclib

(LEE011; Novartis) and Abemaciclib (LY2835219;
Eli Lilly) [30]. Since metastatic disease is thought
to depend on the survival and propagation of CSCs,
then it is perhaps not surprising that we observed that
palbociclib can also be used to target the proliferative
CSC population, in lung, ovarian and breast cancer cell
lines, effectively halting 3D-spheroid formation, with an
IC-50 near 100 nM. Therefore, new clinical trials using
palbociclib to target the proliferative CSC population in
multiple cancer types may be warranted.
Previously, we showed that palbociclib essentially
behaves as a bonafide inhibitor of telomerase function
in normal human fibroblasts [31]. More specifically, we
treated hTERT-immortalized fibroblasts with palbociclib
(0.1, 0.5 and 1 μM) for a period of 36 hours, and then
cell lysates were prepared and subjected to immunoblot
analysis. Importantly, treatment of hTERT-immortalized
fibroblasts with palbociclib dramatically inhibited
RB-phosphorylation, as expected, resulting in the up-

Figure 8: hTERT-high cells show an increased capacity for cell migration, which is strictly dependent on mitochondrial
function. A. Cell migration. A549 and SKOV3 cells stably-transduced with the hTERT-eGFP reporter were subjected to flow cytometry to

isolate the GFP(+) and GFP(-) cell populations. Then, the migratory capacity of these two cell populations was assessed using a modified
“Boyden Chamber” assay. More specifically, the cells were allowed to migrate across an 8 μm pore uncoated membrane for 12-16 hours.
Note that the GFP(+) cell population (derived from A549 or SKOV3 cells) shows a near 2-fold increase in migration, as compared with
the GFP(-) cells. p<0.05 for the A549 and p<0.001 for the SKOV3 cells (Student’s t-test). B. Effects of mitochondrial inhibitors. To assess
whether mitochondrial function is involved in cancer cell migration, mitochondrial inhibitors (either oligomycin A or XCT790) were
placed in both the upper and lower chambers. Note that oligomycin A and XCT790 both effectively inhibited migration in the GFP(+) cell
population. Results are shown as the mean ± SEM, t-test, two-tailed test. *p < 0.05.
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Figure 9: hTERT-high cells are highly proliferative and show an increased capacity for DNA-synthesis. We used EdU

incorporation to monitor DNA-synthesis (S-phase) in the GFP(+) and GFP(-) cell populations. More specifically, cells were treated with
10 uM EdU for 90 minutes and its incorporation was detected according to the recommended staining protocol. Briefly, for the detection
of EdU, we used 405 nm excitation with a violet 450/50 nm bandpass emission filter. Measurement of total DNA content using the flow
cytometer was achieved by using Pacific Blue (picolyl azide). In A549 cells, the GFP(+) population was 8-fold more proliferative than the
GFP(-) cell population. Similarly, in SKOV3 cells, the GFP(+) population was 12-fold more proliferative than the GFP(-) cell population.
Representative histograms show the separation of proliferating (S-phase) and non-proliferating cells. Bar graphs show the mean ± SEM of
three independent experiments. Asterisks (*) denote a significant change, p<0.05.

Figure 10: Targeting CSC propagation with palbociclib, a CDK4/6 inhibitor, in lung, ovarian and breast cancers.

Parental A549 and SKOV3 cells were seeded in low-attachment plates and treated with the indicated concentrations of PD-0332991
(palbociclib) for five days. Then, the number of 3D-spheroids formed was quantitated. Note that palbociclib treatment very effectively
inhibited 3D-sphere formation in A549 (panel A) and SKOV3 cells (panel B), with an IC-50 < 100 nM.

(Continued)
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Figure 10 (Continued): Virtually identical results were also obtained with MCF7 cells (panel C). Data represent three independent
experiments. Results are shown as the mean ± SEM, t-test, two-tailed test. Asterisk (*) depicts significant change, p<0.05. *p < 0.05,
**p < 0.005, ***p < 0.0001.

Figure 11: Telomerase-driven cancer stem-like cells are characterized by an anabolic, migratory and highly proliferative
cellular phenotype. This schematic diagram summarizes the isolation of two distinct populations of cancer cells, based on telomerase

transcriptional activity. A schematic diagram of the hTERT-Promoter-eGFP-Puro-R reporter construct is shown on the right. Note that the
GFP(+) cell population shows significant increases in “stemness”, metabolic activity (both oxidative and glycolytic), cell migration and
proliferation. As a consequence, the propagation of this cell population can be effectively targeted with metabolic inhibitors (oligomycin A,
XCT790, doxycycline, 2-DG) or by using a CDK4/6 inhibitor (palbociclib).
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regulation of markers of cell cycle arrest, such as CDK
inhibitors (p16 and p21), as well as markers of senescence
(β-galactosidase) and autophagy (LC3-I/II) [31]. Thus,
the pharmacological induction of cell cycle arrest with
palbociclib, a CDK4/6 inhibitor, is indeed sufficient to
overcome the state of replicative immortality, normally
conveyed by hTERT expression in fibroblasts. Similar
results were also obtained by acute amino acid starvation
of hTERT over-expressing fibroblasts, possibly explaining
the positive benefits of caloric restriction as an anti-cancer
therapy [31]. Thus, palbociclib could be functionally
repurposed as an FDA-approved “telomerase inhibitor”,
to target replicative immortality in cancer stem-like cells.
Similarly, other groups have shown that the treatment of

cancer cell lines with palbociclib induces the senescence
phenotype [32, 33].
In summary, here we have used an hTERT-eGFP
reporter system to study the functional role of telomerase
activity in generating tumor metabolic heterogeneity. We
observed that hTERT-high CSCs, are more energetically
active and show an increased capacity for migration and
cell proliferation. We propose several new therapeutic
strategies for targeting CSCs, based on this systematic
phenotypic analysis, by employing FDA-approved drugs
such as doxycycline and palbociclib. These approaches
mechanistically target energy metabolism and replicative
immortality in CSCs.

Figure 12: Telomerase-driven cancer stem-like cells: Are they also involved in tumor dormancy? Here, we observed that the

hTERT-high cell population could be further divided into i) proliferating and ii) non-proliferating sub-populations, using EdU incorporation
to monitor DNA-synthesis (S-phase). We speculate that the quiescent hTERT-high CSCs could be involved in tumor dormancy. See the
Discussion section for further elaboration on this point.
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MATERIALS AND METHODS

AldeRed ALDH detection assay

Materials

The AldeRed with 588-A ALDH Detection
Assay (SCR150, Millipore) was used, following the
manufacturer's instructions.

Non-small cell lung cancer (A549) and ovarian
cancer (SKOV3) cell lines were obtained commercially.
The hTERT-eGFP lenti-viral transcriptional reporter
was custom made to our specifications by GeneCopoeia,
and was as we previously described. Briefly, it contains
the 1.5 kB hTERT promoter region for regulating eGFP
expression and a puromycin-resistance cassette as a
selectable marker for deriving stably-transduced cell
populations. Similarly, ER(+) breast cancer cells (MCF7)
were purchased from ATCC. Media for cell cultures
(DMEM, D6546) was from Sigma-Aldrich. Cell culture
media (DMEM/F12) for spheroid culture was purchased
from Life Technologies. XCT790 was purchased from
Tocris. The telomerase inhibitor (MST-312), oligomycin
A, doxycycline and the CDK4/6 inhibitor palbociclib (PD0332991) were all obtained from Sigma-Aldrich.

Mitochondrial staining of live cells with
MitoTracker probes
To evaluate the mitochondrial mass and activity,
adherent cells were stained with MitoTracker Deep
Red (M22426, Life Technologies) or in suspension
with MitoTracker Orange CM-H2TMRos (M7511, Life
Technologies), respectively. Lyophilized MitoTracker
was first dissolved in DMSO to generate a 1 μM stock
solution that was diluted into serum-free DMEM at a final
concentration of 25 nM and 100 nM respectively. Briefly,
cells were cultured for 48 hours and then stained with
MitoTracker for 15 minutes at 37°C. Cells were washed
in PBS and analysed by FACS.

Immunofluorescence analysis

Generation of A549 and SKOV3 lines, harboring
the hTERT-GFP reporter

After six days of treatment with MST-312, the
cells were subjected to immunofluorescence analysis.
Briefly, the cells were incubated with MitoTracker Deep
Red for 20 minutes, and, after washing, were fixed in
4% paraformaldehyde for 15 minutes. Then, cells were
permeabilized for 10 minutes with PBS containing 0.2%
BSA and 0.1% Tween-20. Next, a blocking step with
5% of BSA in PBS was followed by an incubation of 90
minutes with the GFP Tag Antibody, conjugated to the
Alexa Fluor 488 (A21311, Life Technologies). Finally,
slides were washed, stained with DAPI and mounted.
Images were acquired using a fluorescent microscope.

A549 and SKOV3 cell lines were stably-transduced
with the viral supernatants obtained by transfecting
packaging cells with the construct containing GFP under
the transcriptional control of the hTERT promoter region
(hTERT-GFP). After transduction, cancer cell lines were
selected with puromycin for two weeks to generate
hTERT-GFP-A549 cells and hTERT-GFP-SKOV3 cells.

Tumor 3D-spheroid culture
A single cell suspension was prepared using
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924),
and manual disaggregation (25 gauge needle) [34].
Briefly, 2,500 hTERT-GFP A549 cells or 5,000 hTERTGFP SKOV3 cells were plated with spheroids medium
(DMEM-F12/B27/20ng/ml EGF/PenStrep), under nonadherent conditions, in six wells plates coated with
2-hydroxyethylmethacrylate (poly-HEMA, Sigma,
#P3932). Cells were grown for 5 days and maintained
in a humidified incubator at 37°C with 5% (v/v) carbon
dioxide/air. After five days of culture, the number of
spheres >50 μm were counted.

Seahorse metabolic flux analysis
Extracellular acidification rates (ECAR) and
oxygen consumption rates (OCR) were measured using
the Seahorse XFe96 bioenergetic analyzer (Seahorse
Bioscience, MA, USA). GFP(+) and GFP(-) cell
populations were maintained in DMEM supplemented
with 10% FBS (Fetal Bovine Serum), 2 mM GlutaMAX,
and 1% Pen-Strep. Fifteen thousand cells were seeded
for A549 and ten thousand for SKOV3 into XF96well cell culture plates per well, and incubated at
37°C in a 5% CO2 humidified atmosphere. After 20
hours, cells were washed in pre-warmed XF assay
media, as previously described [13]. ECAR and OCR
measurements were normalized by cell number. Data
sets were analyzed using Seahorse XFe-96 software and
Excel software, using Student t-test calculations. All
experiments were performed with six replicates each,
and repeated three times independently.

Flow cytometry analysis and sorting
Cells were subjected to flow cytometric analysis
using the Fortessa™ X-20 and the BD Accuri™ C6.
The GFP(+) (top 10%) and GFP(-) (lowest 10%) cell
populations were separated and collected by using the BD
FACSAria™ III and BD Influx™ cell sorter. Data were
analyzed using FlowJo software (Tree Star, Ashland, OR).
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Semi-quantitative proteomics analysis

proliferation. The Sotgia and Lisanti Laboratories are
currently supported by private donations, the Healthy Life
Foundation (HLF) and by funds from the University of
Salford. The authors would also like to thank Dr. Duncan
L. Smith, who performed the i) unbiased proteomics and
ii) the analysis of the proteomic results, at the Biological
Mass Spectrometry Core Facility, at the Cancer Research
UK Manchester Institute.

Cell lysates were prepared for trypsin digestion
by sequential reduction of disulphide bonds with TCEP
and alkylation with MMTS. Then, the peptides were
extracted and prepared for LC-MS/MS. All LC-MS/MS
analyses were performed on an LTQ Orbitrap XL mass
spectrometer (Thermo Scientific, San Jose, CA) coupled to
an Ultimate 3000 RSLCnano system (Thermo Scientific,
formerly Dionex), The Netherlands). Xcalibur raw data
files acquired on the LTQ-Orbitrap XL were directly
imported into Progenesis LCMS software (Waters Corp.,
Milford, MA, formerly Non-linear dynamics, Newcastle
upon Tyne, UK) for peak detection and alignment. Data
were analyzed using the Mascot search engine. Five
technical replicates were analyzed for each sample
(GFP(+) versus GFP(-); top 10% versus lowest 10%).
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Migration assay
Transwell-24 wells with uncoated permeable
support and 8-μm pores were used (Corning). Thirtythousand (A549) or twenty-thousand (SKOV3) viable
tumor cells were seeded per well, in the upper chamber
and incubated in 5% CO2 at 37°C. The upper side of the
filter was filled with DMEM medium containing 0.1%
BSA. The lower chamber was filled with complete culture
medium containing 10% FBS as chemo-attractant. After
an overnight period, non-migrated cells were removed
from the upper surface of the membrane by scrubbing
with cotton swabs. Inserts were stained with crystal violet
(HT90132, Sigma-Aldrich). All functional experiments
were performed in triplicates. Values for migration were
obtained by counting five fields per membrane (objective
40X) and represent the average of three independent
experiments. Oligomycin A and XCT790 were placed in
both lower and upper chambers.
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